The latest updates on our research and how it is improving people’s lives.
Marie Curie Fellowship awarded to Mariana Borsa
10 July 2020
Congratulations to Mariana Borsa for being awarded the Marie Skłodowska-Curie Actions – Individual Fellowship
Reach for the sky
8 July 2020
A building project to extend the Kennedy Institute of Rheumatology building with a new floor will create much needed space for the Institute to expand, particularly in the areas of data science and clinical trials.
Kennedy Professor leads Cellular Life Theme of Reuben College
1 July 2020
Professor Mark Coles was recently appointed to the governing body of the University’s newest graduate college.
Joint cell discovery offers new hope for people with rheumatoid arthritis
29 June 2020
The key to swift treatments to cure the pain of rheumatoid arthritis has been found in the joints of people with the condition who are in long- term remission.
Sir Marc Feldmann awarded the 2020 Tang Prize in Biopharmaceutical Science
22 June 2020
Recognised for the part he played in the discovery of anti-TNF therapy, Dr Feldmann is now exploring whether the antibody can be effective for COVID-19.
Patients with rheumatic pain increasingly turning to opioids
18 June 2020
Reporting at EULAR, researchers found that opioid use by patients with rheumatic and musculoskeletal pain was on the rise in Europe.
NDORMS professor awarded prestigious Carol Nachman prize for Rheumatology
17 June 2020
Christopher Buckley, Kennedy Professor of Translational Rheumatology at the University of Oxford and Birmingham, has been awarded the 2020 Carol Nachman prize for Rheumatology.
New partnership aims to significantly reduce the incidence of hip and vertebral fractures
16 June 2020
The Capture the Fracture Partnership aims to prevent 250 million fractures by 2025 and combat the global public health burden of osteoporosis.
NDORMS professors serve on NIHR Urgent Public Health Group
11 June 2020
Sion Glyn-Jones and Matt Costa are members of the Covid 19 Urgent Public Health Group coordinating trials to address health impacts of the pandemic.
Oxford leads part of major COVID-19 drugs trial
10 June 2020
NDORMS Professor Duncan Richards and Dr Matt Rowland (Nuffield Department of Clinical Neurosciences) are leading the Oxford arm of a new UK trial to investigate whether administering the anti-inflammatory drug infliximab to patients with COVID-19 can prevent progression to respiratory failure or death.
Could do better: clinical trial reporting fails to live up to the mark
8 June 2020
The statistical analysis and reporting of treatment effects in reports of randomised trials with a binary primary endpoint requires substantial improvement, suggests NDORMS research published in BMC Medicine.
First patient recruit for key drug treatment trial
5 June 2020
A clinical trial to test whether Azithromycin, a commonly used antibiotic, can treat the symptoms of COVID-19 in outpatients has recruited its first patient.
New atlas of stromal cells maps out potential for treating human fibrosis
4 June 2020
Research at the Kennedy Institute reveals sub-populations of stromal cells with distinct functions in human fibrotic disease. These findings could inform development of more specific therapies with fewer off-target effects.
Understanding of inflammatory bowel disease moves a step closer
23 May 2020
Published in Science Immunology, researchers at the Kennedy Institute have identified the role of IRF5 in controlling intestinal inflammation.
Dr. Michael Dustin joins Strategic Research Collaboration with Cue Biopharma
14 May 2020
The research will test innovative technology that harnesses the body’s intrinsic immune system to transform the treatment of cancer and autoimmune diseases.
New weapon identified in arsenal against disease
11 May 2020
Researchers in the Dustin Group reveal supramolecular attack particles are autonomous killing entities released from cytotoxic T lymphocytes
Managing clinical trials during the pandemic
4 May 2020
Duncan Richards, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU) is interviewed about clinical trials and the challenges of running them in a pandemic.
The NDORMS response to COVID-19
30 April 2020
A number of members of the department are actively helping with the response to the COVID pandemic. Playing a key role in research, literature reviews, clinical trials and engineering projects, all have a shared commitment to collaborate globally to tackle the pandemic.